Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide plus fulvestrant with or without sintilimab for recurrent or metastatic HR-positive, HER2-negative breast cancer
ChiCTR2000037642Phase 2Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tucidinostat, fulvestrant and sintilimab in breast cancer (3 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: Objective response rate. Started Sep 2020; status: recruiting.
02
Drugs
tucidinostatfulvestrantsintilimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2000037642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000037642.